Market Overview

Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application

Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application
Related MRK
Bank Of America, JPMorgan, Merck, Stratasys: 'Fast Money' Picks For January 15
How 7 New Laws Affected Stocks In The Last Week
Nasdaq Leads Dow Jones In Bullish Upturn; These 4 Blue Chips Are Outpacing Apple, Forming Chart Patterns (Investor's Business Daily)

Analysts at Barclays no longer hold a bullish view on Merck & Co., Inc. (NYSE: MRK) due to a now diminished potential for its biggest value driver, Keytruda. The firm's Geoff Meacham downgraded Merck's stock rating from Overweight to Equal Weight with a price target slashed from $72 to $62.

Keytruda, Merck's therapy for the treatment of non-small cell lung cancer, was expected to benefit from stronger than expected growth and justify a higher multiple for Merck, the analyst wrote in the downgrade note. But a revision to this thesis is justified after Friday's withdrawal of the EU-KN-0216G filing in the front-line NSCLC on top of previously announced delays in the company's phase 3 KN-189 trial.

Of particular note, a revised outlook for lower Keytruda sales in no way implies that rivals will be leapfrogging Merck, the analyst wrote. But a more likely scenario involves Bristol-Myers Squibb Co (NYSE: BMY) and Roche Holding Ltd. (ADR) (OTC: RHHBY) gaining front-line NSLCL data in late 2017 or early 2018 and "further weigh on sentiment" (see Meacham's track record here).

Meanwhile, some of Merck's other key products, including Januvia and Zepatier, continue to face headwinds, which add to a "more difficult" environment for Merck in the near term. As such, Merck may be in a position where it has to compete in bidding for growth assets to generate a revenue bridge.

Bottom line, the analyst is now modeling Keytruda 2018 sales to be $5.4 billion (versus prior estimate of $6.0 billion) and 2019 sales of $6.6 billion (versus prior estimate of $7.4 billion).

At time of publication, shares of Merck were down 4.6 percent at $55.56.

Related Links:

Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

8 Stocks To Watch For October 30, 2017

Latest Ratings for MRK

Nov 2018CitigroupMaintainsBuyBuy
Oct 2018CitigroupMaintainsBuyBuy
Oct 2018SunTrust Robinson HumphreyMaintainsBuyBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Biotech Downgrades Price Target Analyst Ratings Movers General Best of Benzinga


Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

A New Avenue To Emerging Markets Dividends

8 Technical Levels Highlighted On Monday's PreMarket Prep